A novel radioisotope therapy for children with neuroblastoma
(Kanazawa University) Researchers from Kanazawa University retrospectively analyzed children with refractory or relapsed high-risk neuroblastoma who were treated with high-dose131I-metaiodobenzylguanidine at Kanazawa University Hospital. They showed that within a 5-year period, this therapy could provide a favorable prognosis without severe non-hematological side effects. These findings could provide new insights into a novel treatment option for patients with high-risk neuroblastoma.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Brain | Cancer | Cancer & Oncology | Children | Hematology | Hospitals | Neuroblastoma | Neurology